Literature DB >> 16883551

Preparation of budesonide/gamma-cyclodextrin complexes in supercritical fluids with a novel SEDS method.

Tarja Toropainen1, Sitaram Velaga, Teemu Heikkilä, Laura Matilainen, Pekka Jarho, Johan Carlfors, Vesa-Pekka Lehto, Tomi Järvinen, Kristiina Järvinen.   

Abstract

The aim was to investigate if solid drug/cyclodextrin complexes could be produced in a single-step process with a solution enhanced dispersion by supercritical fluids (SEDS) method. Budesonide and gamma-cyclodextrin (CD) solutions (50% or 99.5% ethanol) were pumped from the same (conventional method) or separate (modified method) containers together with supercritical carbon dioxide through a coaxial nozzle into a particle formation chamber. The pressure was maintained at 100, 150 or 200 bar with a temperature of 40, 60 or 80 degrees C. SEDS-processed powders were characterised with HPLC, DSC and XRPD for budesonide content, complexation and crystallinity. The budesonide dissolution rate was determined in 1% gamma-CD aqueous solution. Solid, white budesonide/gamma-CD complex particles were formed using the conventional and modified SEDS processes. The complexation efficiency was dependent on the processing conditions. For example, with the conventional method (100 bar, 60 degrees C) the yield of the powder was 65+/-12% with 0.14+/-0.02 mg budesonide/mg powder, corresponding to 1:2 drug:CD molar ratio. The dissolution rate of this complexed budesonide (93+/-2% after 15 min) was markedly higher compared to unprocessed micronised budesonide (41+/-10%) and SEDS-processed budesonide without CD (61+/-3%). As a conclusion, SEDS is a novel method to produce solid drug/CD complexes in a single-step process. Copyright (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16883551     DOI: 10.1002/jps.20702

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for Patient-Centred Therapy.

Authors:  Tochukwu C Okwuosa; Beatriz C Pereira; Basel Arafat; Milena Cieszynska; Abdullah Isreb; Mohamed A Alhnan
Journal:  Pharm Res       Date:  2016-12-09       Impact factor: 4.200

2.  Crystal structure changes of gamma-cyclodextrin after the SEDS process in supercritical carbon dioxide affect the dissolution rate of complexed budesonide.

Authors:  Tarja Toropainen; Teemu Heikkilä; Jukka Leppänen; Laura Matilainen; Sitaram Velaga; Pekka Jarho; Johan Carlfors; Vesa-Pekka Lehto; Tomi Järvinen; Kristiina Järvinen
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.580

Review 3.  Supercritical Fluid Technology: An Emphasis on Drug Delivery and Related Biomedical Applications.

Authors:  Ranjith Kumar Kankala; Yu Shrike Zhang; Shi-Bin Wang; Chia-Hung Lee; Ai-Zheng Chen
Journal:  Adv Healthc Mater       Date:  2017-07-28       Impact factor: 9.933

4.  Assessment of the Physical Properties of Inclusion Complexes of Forchlorfenuron and γ-Cyclodextrin Derivatives and Their Promotion of Plant Growth.

Authors:  Yutaka Inoue; Ai Hirano; Isamu Murata; Kenji Kobata; Ikuo Kanamoto
Journal:  ACS Omega       Date:  2018-10-15

5.  Krill Oil-Incorporated Liposomes As An Effective Nanovehicle To Ameliorate The Inflammatory Responses Of DSS-Induced Colitis.

Authors:  Jin-Hee Kim; Soon-Seok Hong; Sun-Young Chang; Myoungsoo Lee; Eun-Hye Lee; Inmoo Rhee; Soo-Jeong Lim
Journal:  Int J Nanomedicine       Date:  2019-11-06

Review 6.  Supercritical Carbon Dioxide as a Green Alternative to Achieve Drug Complexation with Cyclodextrins.

Authors:  Mauro Banchero
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11

Review 7.  Solution-enhanced dispersion by supercritical fluids: an ecofriendly nanonization approach for processing biomaterials and pharmaceutical compounds.

Authors:  Ranjith Kumar Kankala; Biao-Qi Chen; Chen-Guang Liu; Han-Xiao Tang; Shi-Bin Wang; Ai-Zheng Chen
Journal:  Int J Nanomedicine       Date:  2018-07-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.